Taro Pharmaceutical Industries Ltd Quick Ratio (TARO) starting from the fourth quarter 2023 to fourth quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Taro Pharmaceutical Industries Ltd  (NYSE: TARO)

Taro Pharmaceutical Industries Ltd's Quick Ratio

TARO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2023, Quick Ratio deteriorated to 1.89 below Taro Pharmaceutical Industries Ltd's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 362 other companies have achieved higher Quick Ratio than Taro Pharmaceutical Industries Ltd in fourth quarter 2023. While Quick Ratio total ranking in the fourth quarter 2023 has deteriorated compared to the prior quarter from 1327 to 1364.

Explain Quick Ratio?
How much Cash & cash equivalents TARO´s has?
What are TARO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TARO Quick Ratio (Mar 31 2023)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Mar 31 2022)
Q4
Y / Y Current Liabilities Change 728.62 % -42.99 % -42.99 % -55.46 % -93 %
Y / Y Cash & cash equivalent Change 138.89 % -28.66 % -28.66 % -72.94 % -49.74 %
Quick Ratio MRQ 1.89 1.89 1.89 0.92 6.57
TARO's Total Ranking # 1364 # 1327 # 1327 # 1349 # 0
Seq. Current Liabilities Change 0 % 0 % 28 % 547.35 % -93.12 %
Seq. Cash & cash equivalent Change 0 % 0 % 163.69 % -9.4 % -70.14 %



Quick Ratio fourth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 363
Healthcare Sector # 631
Overall Market # 1364


Quick Ratio Statistics
High Average Low
5.22 3.39 0.89
(Mar 31 2018)   (Dec 31 2011)




Financial Statements
Taro Pharmaceutical Industries Ltd's Current Liabilities $ 386 Millions Visit TARO's Balance sheet
Taro Pharmaceutical Industries Ltd's Cash & cash equivalent $ 730 Millions Visit TARO's Balance sheet
Source of TARO's Sales Visit TARO's Sales by Geography


Cumulative Taro Pharmaceutical Industries Ltd's Quick Ratio

TARO's Quick Ratio for the trailling 12 Months

TARO Quick Ratio

 (Mar 31 2023)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Mar 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth -29.76 % -58.46 % -37.07 % -4.82 % 55.71 %
Y / Y Cash & cash equivalent TTM Growth -26.91 % -44.46 % -37.93 % -31.68 % -14.18 %
Quick Ratio TTM 1.69 1.83 1.66 1.55 1.63
Total Ranking TTM # 4411 # 4001 # 4439 # 3790 # 0
Seq. Current Liabilities TTM Growth 30.3 % -20.63 % -17.1 % -18.07 % -22.95 %
Seq. Cash & cash equivalent TTM Growth 20.78 % -12.55 % -11.15 % -22.11 % -8.22 %

Quick ratio ranking by company, industry and sector >> Back to TARO Financial Strength Comparisons >> Go to Compare TARO Quick Ratio to its Competitors

On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q4 2023 to $385.55 millions, cumulative Quick Ratio decreased to 1.69 below the Taro Pharmaceutical Industries Ltd average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 565 other companies have achieved higher Quick Ratio than Taro Pharmaceutical Industries Ltd. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2023 from 4001 to 4411.

Explain Quick Ratio?
How much Cash & cash equivalents TARO´s has?
What are TARO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 566
Healthcare Sector # 1141
Within the Market # 4411


trailing twelve months Quick Ratio Statistics
High Average Low
7.07 2.81 0.71
(Mar 31 2020)   (Mar 31 2022)




Companies with similar Quick Ratio in the quarter ending Mar 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2023 MRQ Cash & cash equivalentMar 31 2023 MRQ Current Liabilities
Lexicon Pharmaceuticals Inc   5.20 $ 105.937  Millions$ 20.371  Millions
Amarin Corp Plcuk  5.19 $ 304.894  Millions$ 58.779  Millions
Evoke Pharma Inc   5.18 $ 8.213  Millions$ 1.586  Millions
Kiniksa Pharmaceuticals International Plc  5.12 $ 187.494  Millions$ 36.587  Millions
Edesa Biotech Inc   5.10 $ 7.645  Millions$ 1.499  Millions
Zymeworks Inc   5.06 $ 340.791  Millions$ 67.319  Millions
Maravai Lifesciences Holdings Inc   5.03 $ 628.273  Millions$ 124.896  Millions
Biora Therapeutics Inc   5.00 $ 30.463  Millions$ 6.096  Millions
Gossamer Bio Inc   4.98 $ 201.856  Millions$ 40.571  Millions
Verastem Inc   4.97 $ 111.204  Millions$ 22.359  Millions
Processa Pharmaceuticals Inc   4.97 $ 10.742  Millions$ 2.161  Millions
Deciphera Pharmaceuticals Inc   4.95 $ 398.633  Millions$ 80.612  Millions
Macrogenics Inc   4.92 $ 224.264  Millions$ 45.614  Millions
Gt Biopharma Inc   4.88 $ 19.899  Millions$ 4.076  Millions
Cue Biopharma Inc   4.79 $ 66.199  Millions$ 13.810  Millions
Nextcure Inc   4.78 $ 29.973  Millions$ 6.266  Millions
Aptinyx Inc   4.78 $ 44.573  Millions$ 9.323  Millions
Blueprint Medicines Corporation  4.76 $ 822.161  Millions$ 172.684  Millions
Cartesian Therapeutics Inc   4.75 $ 125.925  Millions$ 26.531  Millions
Citius Pharmaceuticals Inc   4.69 $ 29.104  Millions$ 6.210  Millions
Lite Strategy Inc   4.64 $ 103.224  Millions$ 22.236  Millions
Zynerba Pharmaceuticals Inc   4.62 $ 44.400  Millions$ 9.610  Millions
Galmed Pharmaceuticals Ltd   4.60 $ 12.642  Millions$ 2.750  Millions
Biomea Fusion Inc   4.60 $ 86.300  Millions$ 18.774  Millions
Mustang Bio inc   4.59 $ 58.098  Millions$ 12.668  Millions
Bridgebio Pharma Inc   4.57 $ 441.490  Millions$ 96.596  Millions
Karyopharm Therapeutics Inc   4.46 $ 261.230  Millions$ 58.578  Millions
Ampio Pharmaceuticals inc   4.45 $ 10.352  Millions$ 2.325  Millions
Hepion Pharmaceuticals Inc   4.39 $ 42.993  Millions$ 9.800  Millions
Aptevo Therapeutics Inc   4.37 $ 25.328  Millions$ 5.797  Millions

Date modified: 2023-06-30T08:25:33+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.